CRIS

CURIS INC

8 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 22

Authorized common stock nearly doubled, creating significant headroom for new share issuance.

dilution risk

90%

neutralMay 22

Company restructured its equity to facilitate easier future capital raises.

capital raise

70%

bearishMay 22

Authorized common stock nearly doubled, creating significant headroom for new share issuance.

dilution risk

90%

neutralMay 22

Company restructured its equity to facilitate easier future capital raises.

capital raise

70%

bearishMay 22

Authorized common stock nearly doubled, creating significant headroom for new share issuance.

dilution risk

90%

neutralMay 22

Company restructured its equity to facilitate easier future capital raises.

capital raise

70%

bearishMay 22

Authorized common stock nearly doubled, creating significant headroom for new share issuance.

dilution risk

90%

neutralMay 22

Company restructured its equity to facilitate easier future capital raises.

capital raise

70%

bearishMay 22

Authorized common stock nearly doubled, creating significant headroom for new share issuance.

dilution risk

90%

neutralMay 22

Company restructured its equity to facilitate easier future capital raises.

capital raise

70%

bearishMay 22

Authorized common stock nearly doubled, creating significant headroom for new share issuance.

dilution risk

90%

neutralMay 22

Company restructured its equity to facilitate easier future capital raises.

capital raise

70%

bullishMay 13

Secured $18.6 million through January 2026 PIPE financing.

capital raise

60%

bearishMay 13

Received Nasdaq delisting determination letter due to bid price non-compliance.

regulatory action

90%

bearishMay 13

Net loss increased significantly to $24.2 million for the quarter.

margin compression

70%

bearishMay 13

Significant increase in common shares outstanding following multiple offerings and PIPE conversion.

dilution risk

80%

bullishMay 13

Secured $18.6 million through January 2026 PIPE financing.

capital raise

60%

bearishMay 13

Received Nasdaq delisting determination letter due to bid price non-compliance.

regulatory action

90%

bearishMay 13

Net loss increased significantly to $24.2 million for the quarter.

margin compression

70%

bearishMay 13

Significant increase in common shares outstanding following multiple offerings and PIPE conversion.

dilution risk

80%

Filing History

8-KMay 22, 2026

Curis's 8-K filing details a comprehensive overhaul of its equity structure, approved by stockholders during its May 2026 annual meeting. The primary outcome is a significant increase in authorized common shares and the elimination of preferred stock series, effectively consolidating the company into a single class of common equity. While management presents this as a move to optimize the balance sheet for scale and strategic optionality, the sheer magnitude of the authorized share increase raises immediate concerns regarding future dilution.

10-QMay 13, 2026

The 10-Q filing reveals a company at a critical crossroads, balancing high-potential clinical catalysts against a backdrop of financial instability. While the strategic consolidation around emavusertib and the successful PIPE financing provide a temporary reprieve, the overarching theme is one of survival. The company has successfully shifted its regulatory strategy toward accelerated pathways, but this progress is offset by a massive accumulated deficit of $1.3 billion and a precarious listing status on the Nasdaq. Investors are essentially betting on a binary outcome: either emavusertib delivers a breakthrough result that attracts a major partner or triggers a regulatory win, or the company exhausts its remaining cash and faces delisting. The tension between the clinical promise of the TakeAim studies and the structural fragility of the balance sheet defines the current risk-reward profile for CRIS.